Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2009 Results
Date:4/29/2009

the company's forward-looking statements include, among others: delays in the completion of Vanda's clinical trials; a failure of Vanda's product candidates to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's product candidates in the marketplace, or a failure to become or remain profitable; Vanda's inability to obtain the capital necessary to fund its research and development activities; Vanda's failure to identify or obtain rights to new product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part I, Item 1A) of Vanda's annual report on Form 10-K/A for the fiscal year ended December 31, 2008 (File No. 001-34186). In addition to the risks described above and in Part I, Item 1A of Vanda's annual report on Form 10-K/A, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda ma
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
2. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
3. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
6. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
8. Onyx Pharmaceuticals Announces First Quarter 2009 Financial Results Teleconference and Webcast
9. Transcept Pharmaceuticals to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
10. Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator
11. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce that ... an e-Journal and producer of Food Labs Conference ... for the co-location of Food Labs Conference to be held ... registration fee to attend the two-day Food Lab Conference, March ...
(Date:1/15/2014)... 2014 Look inside the new Preferred ... the lab, from fluid handling to instruments to supplies. ... when you order. , Preferred Solutions features a ... the L/S® model for precise flow control and dispensing ...
(Date:1/15/2014)... California , January 15, 2014 Oxford ... today announced the appointment of Thomas C Reynolds MD, PhD ... years, development experience gained in the biotechnology industry, most recently ... am delighted to welcome Tom at this transformative time for ...
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... , , PHILADELPHIA and LONDON, Aug. ... the National Institutes of Health (NIH) has chosen Web of ... ( eSPA ). eSPA is an information technology system ... and tracking research outputs and outcomes, including publications and citations. , ...
... 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ... relating to long-term treatment with Stimuvax were presented at ... 13th World Conference on Lung Cancer in San Francisco ... Goss from the Ottawa Hospital Cancer Centre, Ottawa, Ontario, ...
... BEIJING, Aug. 3 /PRNewswire-Asia-FirstCall/ -- Yongye ... a leading developer and,distributor of Shengmingsu branded plant and ... today announced that the number of,independently owned, branded stores ... of June 30, 2009, up from 3,500,as of the ...
Cached Biology Technology:National Institutes of Health Chooses Web of Science(R) to Power electronic Scientific Portfolio Assistant (eSPA) 2Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer 2Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer 3Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer 4Yongye International Announces Branded Store Network Increases Over 40% to 5,000 Stores 2Yongye International Announces Branded Store Network Increases Over 40% to 5,000 Stores 3
(Date:4/22/2014)... in two Minnesota cities demonstrate how communities can ... a ten year program in New England and ... to local conditions. , "Our goal is to ... said program co-leader Latham Stack, of Syntectic International, ... worsened. We help communities move beyond feeling paralyzed ...
(Date:4/21/2014)... is commonly used as a farm soil fertilizer, contains ... from the cows, gut bacteria. The findings, reported in ... American Society for Microbiology, hints that cow manure is ... genes that transfer to bacteria in the soils where ... (AR) genes have already been identified, but the vast ...
(Date:4/21/2014)... are on the decline in the Galpagos. , A new ... indicates numbers of the iconic birds, known for their ... attract mates, have fallen more than 50 percent in less ... is probably due to an unexplained disappearance of sardines from ... at Wake Forest University and the study,s principal investigator. This ...
Breaking Biology News(10 mins):Minnesota projects offer hope and practical help to communities facing more extreme storms 2Cow manure harbors diverse new antibiotic resistance genes 2Cow manure harbors diverse new antibiotic resistance genes 3Lack of breeding threatens blue-footed boobies' survival 2Lack of breeding threatens blue-footed boobies' survival 3
... nanostructures are of great current interest as chemical ... therapeutics," explained David G. Cahill, a Willett Professor ... and Engineering at the University of Illinois at ... the emission of light at a different wavelength ...
... a way to project future habitat locations under ... biodiversity. Associate Professor Grant Wardell-Johnson and Dr ... Biodiversity and Climate, along with lead researcher and ... Wageningen University in the Netherlands, developed an approach ...
... a negative view of climate engineering, the deliberate large-scale ... to a new study. The results are from ... (New Zealand) who have undertaken the first systematic large-scale ... The work is published in Nature Climate ...
Cached Biology News:Understanding secondary light emission by plasmonic nanostructures may improve medical imaging 2Safe havens revealed for biodiversity in a changed climate 2Climate engineering -- what do the public think? 2
... solution is a highly scalable analysis ... data in a workgroup or an ... over 40 leading pharmaceutical, biotechnology, academic ... Workgroup streamlines genomics research at large ...
... scale kinase profiling, quantitative measurement of ... research built on the flexible and ... These microarrays are available as part ... - Peptide Microarray Service. ...
... is an 18 amino acid synthetic peptide whose sequences are derived ... (amino to carboxy terminus): S(21) - S - M - P ... E - A - I - D - K - K ... This peptide may be used for neutralization and control experiments ...
... built on the flexible and powerful ... microarrays are available as part of ... Custom Probe Content ... Thousands of customer specified peptide sequences ...
Biology Products: